Form 10-Q AbCellera Biologics Inc. For: Sep 30
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 [Yahoo! Finance]Yahoo! Finance
- AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024Business Wire
- AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "hold" rating re-affirmed by analysts at Benchmark Co..MarketBeat
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $12.00 price target on the stock, down previously from $14.00.MarketBeat
ABCL
Earnings
- 11/4/24 - Miss
ABCL
Sec Filings
- 11/14/24 - Form SC
- 11/4/24 - Form 8-K
- 10/9/24 - Form SCHEDULE
- ABCL's page on the SEC website